1998-2001: B.S. Ecology and Protection of the Environment. Technical University of Varna, Varna, Bulgaria

2001-2003: B.S. Biology. University of Kansas, Lawrence, KS, USA

2003-2009: Ph.D. Biochemistry and Molecular Genetics, University of Illinois, Chicago, IL, USA

2009-2015: Postdoctoral Fellowships, Stem Cell and Cancer Biology, University of California, Los Angeles, CA, USA

2015-2022: Assistant Professor, Department of Radiology, Stanford University, Stanford, CA, USA

2022: Associate Professor, Department of Radiology, Stanford University, Stanford, CA, USA

2023-present: Associate Professor, Department of Molecular and Medical Pharmacology and Department of Urology (secondary appointment), University of California, Los Angeles, CA, USA


Current Lab Members

  • Ph.D.

Research Description:

The Stoyanova lab develops new cancer early detection approaches and therapeutic strategies for late stage cancers. The current research areas of interest are:

1) Targeted cancer therapies. The Stoyanova lab utilizes multiple approaches to develop new therapeutic strategies for late-stage cancers, including discovery and testing new therapeutic targets and new small molecule inhibitors.

2) Antibody-based therapies for advanced prostate and other metastatic epithelial cancers. The Stoyanova lab develops and tests antibody-based strategies as targeted cancer therapies.

3) Combination therapies for metastatic cancers. We are testing multiple experimental agents in combination with FDA-approved cancer therapies to enhance therapeutic responses.

4) Protein-based biomarkers for cancer early detection. We are interested in the discovery and development of new tissue, blood, and urine-based biomarkers for significant prostate cancer and other epithelial cancers.

5) Imaging modalities for cancer. The lab is interested in developing new positron emission tomography (PET) imaging modalities for epithelial cancers to improve cancer early detection and monitor treatment responses.

The ultimate goals of the laboratory are to improve the early diagnosis and prognosis of clinically significant cancers and guide the development of novel and effective therapeutic strategies for metastatic cancers.